Abstract
To the Editor: The Food and Drug Administration recommends routine laboratory monitoring for patients receiving mycophenolate mofetil because of evidence that mycophenolate mofetil causes neutropenia when used to prevent solid organ transplant rejection.1 Without supporting studies, similar recommendations have been applied to the use of mycophenolate for dermatologic conditions. On the basis of our observations that mycophenolate does not cause neutropenia, hepatic injury, or renal injury when used to treat dermatologic conditions, we performed a retrospective chart review to evaluate the utility of laboratory monitoring of individuals receiving mycophenolate for skin disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
